Raymond James Downgrades G1 Therapeutics (GTHX) to Market Perform
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Price: $7.15 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Raymond James analyst Dane Leone downgraded G1 Therapeutics (NASDAQ: GTHX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on G1 Therapeutics click here. For more ratings news on G1 Therapeutics click here.
Shares of G1 Therapeutics closed at $4.25 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- UBS Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
- Citizens Downgrades Accelerant Holdings (ARX) to Market Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
